NEW YORK, May 15 – Integrative Proteomics said Tuesday that four companies are planning to take equity stakes in the Toronto-based company.

Bruker AXS, Bruker BioSpin, Bruker Daltonics, and Aurora Biosciences all plan to make a strategic equity investment in Integrative Proteomics, the company mentioned in a statement announcing the company’s recent activities. Integrative Proteomics did not offer any details about the size of the stakes. A spokeswoman was not immediately available for comment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.